Study- Actos Doubles Risk of Bladder Cancer
A new Canadian study confirms that taking the diabetes drug Actos for two years can double a person's risk of developing bladder cancer. The study looked at the records of more than 115,000 patients with type 2 diabetes who took Actos (pioglitazone) between 1988 and 2009. The longer a person took Actos, and/or the higher the dosage, the greater the cancer risk. The report was published online on May 31, 2012, by the BMJ.
Details of the Bladder Cancer Study
- Data was collected on nearly 116,000 people.
- Patients were treated for diabetes between 1988 and 2009.
- During follow-up, 470 patients were diagnosed with bladder cancer.
- Among patients who took Actos, there was an 83% increase in bladder cancer risk.
- The risk increased as the cumulative dosage increased- those taking the drug for longer than 2 years had a twofold increase in risk.
Contact an Experienced Actos Attorney
Thomas J. Henry are leaders in the area of product liability litigation. Our Defective Drug and Products Division has extensive knowledge and resources in order to represent our clients efficiently and aggressively. We represent a multitude of people who are battling against manufacturers of food, medical devices and defective pharmaceuticals.
Your choice does matter. If you or a loved one has suffered serious injuries including bladder cancer because of Actos, call the Thomas J. Henry immediately. We are available 24/7, nights and weekends.